Pharvaris N.V. reports developments as a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases, including hereditary angioedema and acquired angioedema due to C1 inhibitor deficiency. Its lead program, deucrictibant, is being developed in immediate-release capsule and extended-release tablet forms for on-demand and prophylactic treatment settings.
Recurring updates include clinical data from the RAPIDe and CHAPTER study programs, patient-reported outcome research, scientific publications, presentations at allergy and immunology meetings, financial results, strategic priorities, shareholder voting matters and capital-structure disclosures.
Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on oral bradykinin-B2-receptor antagonists for hereditary angioedema (HAE), announced CEO Berndt Modig's participation in BioCapital Europe. The event will feature a panel presentation titled “Shaping the New Biotech Reality – Key Lessons from COVID” on March 10, 2021, at 18:30 CET. Additionally, a corporate presentation will occur on March 11, 2021, at 14:50 CET. Both presentations will be accessible for 30 days on the Pharvaris website.
Pharvaris (Nasdaq: PHVS) has initiated the RAPIDe-1 Phase 2 study, dosing the first patient for its oral bradykinin B2 receptor antagonist, PHVS416, targeting hereditary angioedema (HAE) treatment. The trial will evaluate the efficacy, safety, and pharmacokinetics of PHVS416 in 54 adult patients with HAE type 1 or 2 across North America and Europe. The results aim to provide rapid and convenient on-demand treatment for HAE attacks, offering an alternative to injectable therapies. Pharvaris' approach could significantly enhance patient care for this rare condition.
Pharvaris (Nasdaq: PHVS) announced the presentation of clinical data for PHA121 at the 2021 AAAAI Virtual Annual Meeting. This single-dose treatment showed effective bradykinin inhibition in healthy volunteers, supporting initiation of studies in hereditary angioedema (HAE) patients this year. Results indicated that PHA121 achieves therapeutic levels quickly, with significant pharmacodynamic effects compared to icatibant. Adverse events were reported in 25% of subjects, consistent with placebo, and were mild or moderate. The company aims to develop both on-demand and prophylactic treatments using PHA121.
Pharvaris N.V. (Nasdaq: PHVS) has successfully closed its initial public offering, issuing 9,511,075 ordinary shares at $20.00 each, generating approximately $190.2 million in gross proceeds. This includes the full exercise of the underwriters' option to purchase an additional 1,240,575 shares. The shares commenced trading on February 5, 2021. Pharvaris focuses on developing small molecule bradykinin-B2-receptor antagonists for hereditary angioedema (HAE) and other related conditions, exemplifying its commitment to innovative therapeutic solutions.
Pharvaris N.V., a clinical-stage biopharmaceutical company, announced the pricing of its upsized initial public offering of 8,270,500 ordinary shares at $20.00 per share, totaling gross proceeds of approximately $165.4 million. The offering includes a 30-day over-allotment option for an additional 1,240,575 shares. Shares will trade on the Nasdaq under the symbol PHVS starting February 5, 2021. The offering aims to advance Pharvaris's development of oral bradykinin-B2-receptor antagonists for hereditary angioedema and other conditions.